Our values range below these reported values not only because we used targeted biopsies but also due to our distinct study objects, representing healthy individuals with extremely low PSA values and not patients with clinical suspicion for prostate cancer; thus, resulting in a much lower pre-test probability for prostate cancer as compared to a patient cohort with a high level of suspicion for prostate cancer. The gene discussed is KLK3; the disease is Familial prostate cancer.